LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Начало・Списък с акции・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Затворен

СекторЗдравеопазване

54.89 0.96

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

54.31

Максимум

55.05

Ключови измерители
By Trading Economics
Приходи	1.6B 2.7B
Продажби	-1B 11B
P/E Средно за сектора	15.392 49.888
EPS	1.31
Дивидентна доходност	4.37
Марж на печалбата	23.309
Служители	32,500
EBITDA	1.5B 3.7B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+16.25% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	4.37% 2.38%
Следващи печалби	30.07.2026 г.
Следваща дата на дивидент	31.07.2026 г.
Следваща дата на екс-дивидент	2.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-5.8B 112B
Предишно отваряне	53.93
Предишно затваряне	54.89

Настроения в новините

By Acuity

43%

57%

132 / 344 Класиране в Healthcare

Bristol-Myers Squibb Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.06.2026 г., 13:08 ч. UTC

Печалби

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

12.05.2026 г., 06:42 ч. UTC

Значими двигатели на пазара

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

30.04.2026 г., 11:14 ч. UTC

Печалби

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

29.05.2026 г., 08:15 ч. UTC

Пазарно говорене

Печалби

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

5.05.2026 г., 18:12 ч. UTC

Печалби

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5.05.2026 г., 13:54 ч. UTC

Печалби

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30.04.2026 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14.04.2026 г., 14:13 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 12:57 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 11:19 ч. UTC

Печалби

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14.04.2026 г., 10:34 ч. UTC

Печалби

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13.04.2026 г., 21:23 ч. UTC

Печалби

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Bristol-Myers Squibb Co. Прогноза

Ценова цел

By TipRanks

16.25% нагоре

12-месечна прогноза

Среден 63.31 USD 16.25%

Висок 75 USD

Нисък 40 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Bristol-Myers Squibb Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Bristol-Myers Squibb Co. през последните 3 месеца.

Настроение

By Acuity

132 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.